TrialsgrambetaRCTs are beautiful

PARADIGM-HF

2014

Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality

In 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.

Result

Efficacy: CV death or HF hospitalisationHR 0.8

Below 1 favours sacubitril/valsartan, above 1 favours enalapril.

Event rates
Absolute difference
4.7 points

The absolute difference is derived from the event rates.

Also reported: All-cause mortality also reduced.

Original publication
Subtopic
ARNI
Design
Double-blind RCT, terminated early
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
McMurray JJV, et al. N Engl J Med. 2014;371(11):993-1004.doi 10.1056/NEJMoa1409077

Discussion & critique

Run-in period excluded intolerant patients (~ 20 %), which may inflate efficacy estimates. ARNI replaced ACEi as preferred RAAS-blocker in HFrEF guidelines.

Discussed in podcasts